Introduction
Massive segmental bony defects often occur following trauma. A segmental defect fracture generally does not heal, but instead ends up as a non-union if it is not treated by extended and complicated surgical methods. Although conventional bone grafting is currently considered to be the method of choice for the treatment of segmental defect fractures, the procedure is often unsuccessful. 1, 2 Furthermore, the donor sites available in the skeletal system for harvesting autogenous spongious or corticospongious bone grafts are limited. Additionally, there are a number of complications related to the surgical procedure of harvesting autologous bone grafts, such as local infections, paresthesias, and pain at the donor site. 3 Unsatisfactory results after surgical treatment of post-traumatic segmental bone defects are described in up to 30% of cases. 4, 5 Segmental defects after tumor surgery are even more challenging. The area of bone resection is generally large, defect was predominantly fibrotic and sparsely ossified. At the end of the 12-week experiment, the control femora still showed no radiological signs of stable healing. The difference in radiologically defined healing between the experimental and control groups was statistically significant (P Ͻ 0.002). Biomechanical testing of the femora at 12 weeks demonstrated statistically significant increases in the mean bending strength (P Ͻ 0.005) and bending stiffness (P Ͻ 0.05) of the animals treated with the BMP-2 gene. Direct, local adenoviral delivery of an osteogenic gene thus led to the healing of an osseous lesion that otherwise would not do so. These promising data encourage the further development of genetic approaches to enhancing bone healing. Gene Therapy (2000) 7, 734-739.
all osteoconductive and osteoinductive material has been completely removed, and often the only reasonable therapy is an amputation of an extremity because of the complete lack of bony substance.
Different osteoinductive and osteoconductive methods are currently under investigation for developing adequate alternatives to bone grafting. One attractive approach makes use of the powerful osteogenic properties of certain growth factors. Members of the transforming growth factor-␤ family of growth factors, including the bone morphogenetic proteins (BMPs), have diverse effects on the growth and differentiation of mesenchymal cells, as well as on their ability to synthesize matrix. [6] [7] [8] [9] An interesting feature of some of these growth factors is their osteoinductivity, the competence to induce bone formation. This has been demonstrated in vivo by their ability to induce bone formation at heterotopic sites and in different bone defect models. 7, 8, 10 These factors are thus of potential use in enhancing the process of fracture healing. The osteoinductive properties of certain bone morphogenetic proteins such as BMPs-2, -4, and -7 have been established in animal models. 7, 10, 11 The clinical application of such potent osteoinductive substances may be limited by their short biological halflives. Gene transfer is one promising method being evaluated to overcome this problem. Delivery of genes encoding growth factors can provide high, sustained concentrations of these factors locally for extended periods of time. Moreover, endogenously synthesized proteins, in contrast to exogenous recombinant proteins, may have greater biological effectiveness. 12, 13 Transfer of osteoinductive genes to laboratory animals results in local bone formation. [14] [15] [16] [17] [18] [19] [20] Promising pre-clinical data have been reported for the healing of bone by ex vivo 14, 15 and in vivo 16, 17 approaches.
We have previously described a bone segmental defect model in the lapine femur. 21 Preliminary studies using this model have shown that adenoviral vectors can transfer marker genes into the defect, with high levels of local transgene expression. Gene expression persisted up to 6 weeks in bone, and up to 4 weeks in the surrounding soft tissues. 21 The current investigation used this model to determine whether direct, in vivo gene therapy based on adenoviral vectors carrying the BMP-2 gene could accelerate callus formation, as well as ossification and mineralisation, within a segmental long bone defect, and improve the biomechanical properties of the newly formed bone.
Results
Production of biologically active BMP-2 after adenoviral gene delivery Recombinant adenoviral vectors carrying a human BMP-2 cDNA were generated by standard techniques (see Gene Therapy phosphatase. Transduction with 10 10 particles of the virus carrying BMP-2 resulted in detachment of all cells from the culture dish and elimination of all alkaline phosphatase production. These cells were presumably dead. This was not observed when the same amount of an adenoviral vector encoding marker genes was used.
Radiological analysis
Segmental defects were surgically created in the femora of New Zealand white rabbits. 21 Adenoviruses carrying either the BMP-2 or luciferase genes were injected into the defect and the rabbits monitored radiologically for 12 weeks.
Immediately after surgery the size of the defect between the distal and the proximal femoral segments was identical for all groups (Figure 2a , e). All rabbits developed mineralisation within the defect area. Ossification leading to a connection of the femur segments could be seen in the defect area after 5 weeks in all but one of the rabbits in the group of rabbits receiving the BMP-2 gene (Figure 2b ). In contrast, the rabbits in the control group had only a cloudy mineralization in the defect area without reconnection between the ends of the femur segments ( Figure 2f ). Seven weeks after operation the defect area was restored in all defects receiving the BMP-2 gene, with filling of at least 75% of the defect area with cancellous ossification (Figure 2c ). Healed defects are defined as those with bone bridging at least 75% of the defect site. By this definition, all defects treated with the BMP-2 gene healed their gaps by 12 weeks after surgery (Figure 2d ), whereas none of the control rabbits did so (Figure 2h ). These differences are statistically significant, using the Fisher's exact test (P Ͻ 0.002). Even after 12 weeks, all but one of the rabbits in the control group had only a thin bony connection between the cut ends of the femur, mostly attached to the implant. The remaining rabbit did not show any evidence of healing and developed a pseudarthrosis, which broke during plate removal.
Figure 2 Radiological analysis of defects treated with BMP-2 and the luciferase genes. Representative radiographs of defects treated with the BMP-2 gene at the time of operation (a) and 5 weeks (b), 7 weeks (c) and 12 weeks (d) after the operation. Representative radiographs of defects receiving the luciferase gene at the time of operation (e) and 5 weeks (f), 7 weeks (g) and 12 weeks (h) after the operation.

Histology
Representative rabbits were killed 8 weeks after surgery and the defects examined histologically. The histology of the undecalcified femur confirmed that introduction of the BMP-2 gene led to complete ossification across the entire defect after 8 weeks. Von Kossa staining showed complete recreation of cancellous bone and early transformation to cortical bone in the former defect area (Figure 3a) . In contrast, the defect area of the control femur receiving the luciferase gene was dominated by an extended central fibrosis, surrounded by cloudy new bone formation and only a faint connection of the distal and proximal femoral segment along the plate ( Figure  3b ).
Biomechanical testing
At the end of the 12-week experiment, rabbits were killed and their femora excised and subjected to biomechanical testing. The results of the roentgenographic analysis were supported by the biomechanical findings (Figure 4 ). After removal of the internal plate fixation and the cerclage wires, one specimen of the control group had to be excluded from further analysis, because it broke during the procedure. All remaining femora, treated either with the BMP-2 or with the luciferase gene, underwent biomechanical testing. One specimen from the control rabbits showed gross motion at the bony gap site with gentle manipulation, supporting the radiographic findings of a pseudarthrosis. The mean bending strength of specimens derived from the rabbits receiving the BMP-2 gene (170.7 ± 20.6 Newtons) was significantly higher (P Ͻ 0.005) than the control specimens (70.8 ± 24.4 Newtons). These findings were supported by the results of the testing of diaphyseal stiffness. The bending stiffness of the femora receiving the BMP-2 gene was significantly higher (84.0 ± 10.2 Newtons/mm) than the stiffness of femora receiving the luciferase gene (49.5 ± 17.4 Newtons/mm) (P Ͻ 0.05) (Figure 4 ).
Discussion
Local delivery of growth factor genes is likely to be more effective in bone healing than the application of pure recombinant proteins. 12, 13 Moreover, the application of gene therapy vectors, unlike present surgical approaches to non-unions, does not further destroy the integrity of the injured tissue, and it may be necessary to administer the therapeutic vectors only once. The local overexpression of growth factors for 3 to 6 weeks 21 might explain the strong acceleration of new bone formation seen in our experiments.
The experiments presented here demonstrate the a b
Figure 3 Histological analysis of defects 8 weeks post-operatively. Von Kossa staining of the former segmental defect area. In defects treated with the BMP-2 gene (a) there is complete bridging with cancellous bone and early formation of cortical bone 8 weeks after gene transfer. In contrast, the defect area of the control femur receiving the luciferase gene (b) lacks cancellous bone. Instead it is dominated by an extended central fibrosis, surrounded by cloudy new bone formation and only a faint connection of the distal and proximal femoral segment along the plate.
Figure 4 Effect of gene transfer on the mechanical properties of the femora 12 weeks post-operatively.
Gene Therapy ability of the BMP-2 gene delivered locally by an adenoviral vector, to enhance healing of a lapine long bone defect. Radiographic and histologic results show that bridging of the segmental defect was gained after 8 weeks, whereas there was only a faint bridging or no bridging in the control defects. Twelve weeks postoperatively biomechanical testing confirmed that the newly formed bone in the defects receiving the BMP-2 gene was significantly stronger and stiffer than controls. Indeed, one of the control rabbits developed a non-union and another formed new bone so weak that it fractured upon plate removal. Thus bone formation can be accelerated in this model by in vivo gene therapy using first generation adenoviral vectors. The first use of gene transfer in promoting bone deposition was reported by Fang et al, 16 who implanted naked, plasmid DNA containing BMP-4 and parathyroid hormone combined with a collagenous scaffold, into segmental defects in rats, and subsequently dogs. 17 Our method, in contrast, is viral and does not require scaffolds. Indeed, in an earlier study using this model, collagen was found to impede in vivo cell transduction by adenoviral vectors. 21 This study also revealed very high expression of the transgene by the skeletal muscle surrounding the defect. Gene expression persisted locally for approximately 3 weeks in the soft tissues surrounding the defect, whereas transgene expression from cut ends of the bone lasted for 6 weeks. The present data indicate that this period of time is appropriate for enhancing bone healing in healthy rabbits.
In view of the high levels of gene expression within the surrounding muscle, 21 it is surprising that we did not observe more ectopic bone formation in rabbits treated with the BMP-2 gene than in control rabbits. It is possible that very high levels of BMP-2 gene expression within muscle leads to suppression of bone formation in this microenvironment by mechanisms related to the apparent death of osteoprogenitor cells reported in Figure 1 . Cytotoxicity following infection with high concentrations of adenovirus carrying BMP-2 is an unexpected, novel observation. Although the mechanisms underlying this effect are unknown, they cannot be trivially accounted for by the high viral load as infection with equally high, or even higher concentrations of adenovirus carrying marker genes does not do this. It would be valuable to know whether equivalent amounts of recombinant BMP-2 are also cytotoxic, or whether this only occurs after gene delivery under conditions where BMP-2 accumulates intracellularly. Mason et al 22 have observed a toxic effect when infecting periosteal cells with vectors carrying the BMP-7 gene. According to these authors, cell death resulted from excessive formation of hydroxyapatite. This possibility was not explored in the present study. However, the apparent ability of high expression of BMPs to cause cell death needs to be taken into account when developing clinical protocols; more is not necessarily better.
Lieberman et al 14, 15 have also used adenoviral vectors carrying the BMP-2 gene to accelerate healing of a segmental defect, but in this case it was achieved by ex vivo delivery via bone marrow cells. In a related application, Boden et al 18 transfected bone marrow cells with plasmids encoding the LIM mineralisation protein and in an ex vivo fashion, used these to enhance spinal fusion in rats. Ex vivo methods are far more cumbersome than the in vivo system described here, and their clinical application is more complicated.
In contrast to most other investigations, 6, 8, [14] [15] [16] [17] 23 ours did not rely upon supporting biomaterials, scaffolds, or matrices, which are generally implanted along with the growth factors cells or genes. The transduced cells act as natural, local sites which continuously produce the growth factors encoded by the transgenes, thereby enhancing immigration of stem cells, the differentiation of osteoprogenitor cells and the deposition of bone. [24] [25] [26] The muscle surrounding the defect chamber might serve as a natural matrix to guide the bridging of segmental defects, as well as a possible local source of osteoprogenitor cells. Indeed BMP-2 is known to inhibit myogenic differentiation and to convert the differentiation of myoblasts into the osteoblast lineage. 26, 27 The local environment, the duration of transgene expression, and the cellular production of BMP-2 might explain why bone restoration was possible without using additional osteoconductive materials.
Materials and methods
Study design
An osteoperiostal segmental defect was created in the left femur of each of 13 New Zealand white rabbits by the method of Baltzer et al 21 and stabilised by plate fixation. Adenoviral vectors (2 × 10 10 particles) were injected into the site of the defect. Seven rabbits received virus carrying the BMP-2 gene, and six control rabbits received virus carrying the luciferase gene. Bone healing was monitored radiographically. After 8 weeks, the defects receiving the BMP-2 gene had healed radiographically. To confirm this by independent criteria, representative rabbits were killed at this time for histological evaluation. All remaining rabbits were killed 12 weeks after surgery and the site of bone healing evaluated biomechanically.
Vectors
A cDNA encoding human BMP-2 was kindly provided by the Genetics Institute (Cambridge, MA, USA). This DNA was inserted into the E1 region of a serotype 5 adenovirus deleted in the E1 and E3 regions of the genome, using cre-lox recombination. 28 A human CMV early promoter was used to drive gene expression. A similar vector containing the luciferase marker gene was generated by the same method. Recombinant virus was propagated in the permissive cell line 293 and purified by standard cesium chloride banding techniques. Viral titers were determined by optical density at 260 nm (1 unit = 10 12 virions/ml). The ability of the vector to induce BMP-2-expression after cell transduction and the biological activity of the BMP-2 were tested in vitro using a bioassay based on the responses of a bone marrow stromal cell line. 29 BMP-2 increases alkaline phosphatase activity in these cells. , or 10 10 particles of the adenoviruses carrying either the BMP-2 gene or, as a control, the luciferase gene. Alkaline phosphatase activity was determined 48 h after transduction by the methods described in Ref. 29 .
Animal model
The animal model used in these experiments has been described in detail in Ref. 21 . Briefly, a 1.3 cm segmental, osteoperiosteal defect, representing approximately 12% of the total length of the femur, was surgically created in skeletally mature New Zealand white rabbits. The defect was stabilised by plating and cerclage wires. The surrounding muscle was closed around the lesion, producing a closed chamber between the cut ends of the bone.
Radiographic analysis
Antero-posterior and lateral radiographs of the operated left femur were taken immediately after surgery to exclude animals with pre-existing and intra-operative bone pathologies, and to ensure the correct placement of the screws. Antero-posterior radiography was repeated at 2, 5, 7, and 12 weeks. The segmental defects were defined as healed if the extent of the defect filling was radiologically more than 75%.
Histologic analysis
Because the radiographic data suggested healing in the group of rabbits receiving the BMP-2 gene at 7 weeks, two representative rabbits were killed for histological analysis 8 weeks after operation. Undecalcified sections were stained with the Von Kossa stain after plastic embedding with Technovit 7200 VLC (Fa Kulzer, Norderstedt, Germany), and cutting of 300 m sections with a diamant-coated saw (Exact Fa Messner, Norderstedt, Germany). The sections were made parallel to the long axis of the bone, extending over the entire length of the defect.
Mechanical testing
Rabbits were killed 12 weeks post-operatively, and the soft tissues stripped from the left femora. All femora were removed and stored frozen at −80°C immediately after preparation. The femora were thawed for 24 h in a refrigerator before testing. Each femur was placed in a three-point bending system which provided an unsupported length of 4.5 cm. The ends of the femur were not fixed. The condyles were directed upwards, such that the anterior surface of the femur was placed in tension by the test. Load was applied in posterior-to-anterior direction at the mid-point of the unsupported length, approximately in the middle of the diaphysis.
Testing was conducted on an Instron 8500 servohydralic testing system (Instron, Canton, MA, USA) using an Instron 2500 lbf load cell. Deformation was measured using the internal system LVDT. Data were acquired at a rate of 50 Hz using Instron's MAX software and was analyzed using MSExcel. A maximum deflection of 1 cm was applied at a rate of 0.5 cm/min or 0.0833 mm/s. The test was stopped following fracture.
Statistical analysis
The data for the mechanical testing were examined by Student's unpaired t test. The data for the radiographic analysis of healing were examined statistically by a twoby-two Fisher's exact test to compare treatment groups and control rabbits.
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